Genipin and UV-CLX is safe and effective for keratoconus

Article

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus, claims a study in Molecular Vision.

Dr Marcel Y. Avila et al., Department of Ophthalmology, Facultad de Medicina, Universidad Nacional de Colombia, Bogota, Colombia, separated porcine eyes into three groups comprising genipin 0.25% UV-CLX (clinical crosslinking procedure), a glutaraldehyde 0.1% (gold standard crosslinker) and control.

A pressure sensor cannulated to the anterior chamber continuously monitored all groups. Changes in ocular pressure due to ocular volume were evaluated. The exponential of polynomial quadratic fit was used to calculate ocular rigidity. A viability assay with alizarin red staining was used to assess endothelial damage.

In the genpin and UV-CLX globes where the cornea was stiffened there were significant changes in IOP. Mean ocular rigidity coefficient was 0.0078 mmHg/μL for genpin, 0.0065 mmHg/μL for UV-CLX, 0.0092 mmHg/μL for glutaraldehide and 0.0046 mmHg/μL for control eyes.

In the control group endothelial damage was 5.9±1.8%, 10.3±1.7% in UV-CLX, 9.4±1.5% in Genipin 0.25% and 40.1±6.2% in glutaraldehide. In the UV-CLX group there was a significant reduction of keratocites.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.